 |
 |

Family-Focused Treatment for Adolescents With Bipolar DisorderResults of a 2-Year Randomized Trial
David J. Miklowitz, PhD;
David A. Axelson, MD;
Boris Birmaher, MD;
Elizabeth L. George, PhD;
Dawn O. Taylor, PhD;
Christopher D. Schneck, MD;
Carol A. Beresford, MD;
L. Miriam Dickinson, PhD;
W. Edward Craighead, PhD;
David A. Brent, MD
Arch Gen Psychiatry. 2008;65(9):1053-1061.
Context Family interventions have been found to hasten episode recovery and delay recurrences among adults with bipolar disorder.
Objective To examine the benefits of family-focused treatment for adolescents (FFT-A) and pharmacotherapy in the 2-year course of adolescent bipolar disorder.
Design Two-site outpatient randomized controlled trial with 2-year follow-up.
Patients A referred sample of 58 adolescents (mean [SD] age, 14.5 [1.6] years) with bipolar I (n = 38), II (n = 6), or not otherwise specified disorder (n = 14) with a mood episode in the prior 3 months.
Interventions Patients were randomly assigned to FFT-A and protocol pharmacotherapy (n = 30) or enhanced care (EC) and protocol pharmacotherapy (n = 28). The FFT-A consisted of 21 sessions in 9 months of psychoeducation, communication training, and problem-solving skills training. The EC consisted of 3 family sessions focused on relapse prevention.
Main Outcome Measures Independent "blind" evaluators assessed patients every 3 to 6 months for 2 years. Outcomes included time to recovery from the index episode, time to recurrence, weeks in episode or remission, and mood symptom severity scores.
Results Analyses were by intent to treat. Rates of 2-year study completion did not differ across the FFT-A (60.0%) and EC conditions (64.3%). Although there were no group differences in rates of recovery from the index episode, patients in FFT-A recovered from their baseline depressive symptoms faster than patients in EC (hazard ratio, 1.85; 95% confidence interval, 1.04-3.29; P = .04). The groups did not differ in time to recurrence of depression or mania, but patients in FFT-A spent fewer weeks in depressive episodes and had a more favorable trajectory of depression symptoms for 2 years.
Conclusions Family-focused therapy is effective in combination with pharmacotherapy in stabilizing bipolar depressive symptoms among adolescents. To establish full recovery, FFT-A may need to be supplemented with systematic care interventions effective for mania symptoms.
Trial Registration clinicaltrials.gov Identifier NCT00571402.
Author Affiliations: Department of Psychology, University of Colorado, Boulder (Drs Miklowitz, George, Taylor, and Craighead); Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (Drs Axelson, Birmaher, and Brent); and Department of Psychiatry, University of Colorado Health Sciences Center, Denver (Drs Miklowitz, Schneck, Beresford, and Dickinson).
CiteULike Connotea Delicious Digg Facebook Reddit Technorati Twitter
What's this?
RELATED LETTER
Family-Focused Treatment for Adolescents With Bipolar Disorder
Christine Kuehner
Arch Gen Psychiatry. 2009;66(8):915.
EXTRACT
| FULL TEXT
RELATED ARTICLE
This Month in Archives of General Psychiatry
Arch Gen Psychiatry. 2008;65(9):991.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Recent Progress in Understanding Pediatric Bipolar Disorder
Goldstein
Arch Pediatr Adolesc Med 2012;0:archpediatrics.2011.832v1-10.
ABSTRACT
| FULL TEXT
Pharmacological treatment of depression and bipolar disorder in children and adolescents
Dubicka et al.
Adv. Psychiatr. Treat. 2010;16:402-412.
ABSTRACT
| FULL TEXT
Pediatric Bipolar Disorder: More Than a Temper Problem
Goldstein
Pediatrics 2010;125:1283-1285.
FULL TEXT
Psychoeducation for bipolar disorder
Smith et al.
Adv. Psychiatr. Treat. 2010;16:147-154.
ABSTRACT
| FULL TEXT
Family-Focused Treatment for Adolescents With Bipolar Disorder
Kuehner
Arch Gen Psychiatry 2009;66:915-915.
FULL TEXT
Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology
Goodwin and Consensus Group of the British Association for Psy
J Psychopharmacol 2009;23:346-388.
ABSTRACT
|